Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures:a real-world experience in eastern China

Epilepsy is one of the most common neurological diseases which affects approximately 70 million people worldwide each year. So far, the anti-seizure medications (ASMs) are still the first choice for epilepsy. In the last few years, more and more epileptologists chose newer ASMs such as perampanel (PER) monotherapy for prescription in patients with focal-onset seizure.

0